BCL2 and axial length measurement: In this multi-center study, we report promising outcomes in a cohort of 26 AL patients treated with the BCL-2 inhibitor venetoclax outside of a clinical study, with an ORR of 88%, CR rate of 32%, mDOR of 25 m, median EFS of 25 m, and median OS of 33 m.